Benitec Biopharma (BNTC) vs Enanta Pharmaceuticals (ENTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Benitec Biopharma (BNTC) over the past year, gaining 11.6% versus a loss of 34.8%. Over five years, ENTA leads with a -82.7% price change compared with -85.3% for BNTC. Enanta Pharmaceuticals is the larger company by market cap ($360.3 million vs $313.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | ENTA |
|---|---|---|
| Share price | $8.99 | $12.37 |
| Market cap | $313.60M | $360.28M |
| 1-day change | -0.11% | +1.64% |
| YTD return | -33.26% | -21.56% |
| 1-year return | -34.76% | +11.64% |
| 5-year return | -85.27% | -82.69% |
| EPS (TTM) | $-0.98 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $17.15 |
| 52-week low | $8.52 | $10.20 |
| Distance from 52-week high | -46.36% | -27.87% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +170.63% | +76.48% |
| Average volume | 150.34K | 227.13K |
| Shares outstanding | 34.88M | 29.13M |
| Employees | 24 | 120 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed BNTC by 46.4 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Healthcare · Biotechnology · 24 employees
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Healthcare · Biotechnology · 120 employees
BNTC vs ENTA FAQ
Which is bigger, Benitec Biopharma or Enanta Pharmaceuticals?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $360.28M compared with $313.60M for Benitec Biopharma (BNTC).
Which stock has performed better over the past year, BNTC or ENTA?
ENTA returned +11.64% over the past 12 months, compared with -34.76% for BNTC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Enanta Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.